Oncogenic KRAS induces cell proliferation and transformation, but little is known about its effects on cell division. Functional genetic screens have recently revealed that cancer cell lines expressing oncogenic KRAS are sensitive to interference with mitosis, but neither the mechanism nor the uniformity of anti-mitotic drug sensitivity connected with mutant KRAS expression are yet clear. Here, we report that acute expression of oncogenic KRAS in HeLa cells induces mitotic delay and defects in chromosome segregation through mitogen-activated protein kinase (MAPK) pathway activation and de-regulated expression of several mitosis-related genes. These anomalies are accompanied by increased sensitivity to anti-mitotic agents, a phenotype dependent on the transcription factor MYC and its downstream target anti-apoptotic protein BCL-XL. Unexpectedly, we find no correlation between KRAS mutational status or MYC expression levels and anti-mitotic drug sensitivity when surveying a large database of anti-cancer drug responses. However, we report that the co-existence of KRAS mutations and high MYC expression predicts anti-mitotic drug sensitivity. Our findings reveal a novel function of oncogenic KRAS in regulating accurate mitotic progression and suggest new avenues to therapeutically target KRAS-mutant tumours and stratify patients in ongoing clinical trials of antimitotic drugs.
. To explore this, we generated a stable cell line where expression of KRAS G12D can be induced by treatment with doxycycline (Dox). Figure 1a shows expression of ectopic KRAS G12D after a 24-hour treatment of HeLa FRT/ TO KRAS G12D cells (from here on, termed HeLaG12D) with doxycycline. The transgene has a single myc tag at its amino terminus, distinguishing it in size from the endogenous RAS proteins. As expected, activation of the downstream MAPK pathway occurs upon doxycycline treatment, as detected by increased phosphorylation and nuclear translocation of Extracellular signal-regulated kinase (ERK) 1 and 2 ( Fig. 1a and Supplementary Fig. S1 ). As a positive control, we treated HeLaG12D cells with Extracellular Growth Factor (EGF), which triggers a considerably higher increase in phosphorylated ERK1/2. Known downstream effects of RAS-MAPK pathway activation such as elevated expression and/or stabilization of MYC and tumour suppressor ARF are also observed at later time points (5 days post-doxycycline; Fig. 1b) , demonstrating that this model system recapitulates several characteristics of RAS pathway activation.
In order to analyse mitotic progression and chromosome behaviour shortly after expression of KRAS G12D , we stably integrated GFP-tagged histone H2B into HeLaG12D cells, and performed time-lapse imaging 24 h after addition of doxycycline. As shown in Fig. 1c , untreated cells spent an average of 50 minutes in mitosis (scored from nuclear envelope breakdown [NEB] to anaphase; n = 250 cells), while a significant proportion of doxycycline-treated cells showed delayed progression through mitosis (mean value of 95 minutes; n = 252 cells). Closer inspection of the time-lapse data revealed that KRAS G12D -expressing HeLa cells displayed a variety of mitotic defects including errors in chromosome alignment and segregation ( Fig. 1d and Supplementary Fig. S2 ). We note that, in most cases, these defects were relatively mild, with 1-2 unaligned or lagging chromosomes in anaphase, consistent with the fact that KRAS is not a direct mediator of mitosis, and instead suggesting that oncogenic KRAS may exert subtle regulatory effects on the mitotic machinery. Importantly, neither parental cells devoid of transgene expression nor cells expressing wild-type KRAS showed mitotic delay or defects in chromosome alignment or segregation upon doxycycline treatment (Fig. 1c,d and Supplementary Fig. S3 ). Taken together, these results indicate that acute expression of oncogenic KRAS triggers aberrant mitotic division associated with delays in progression through mitosis.
In order to explore the mechanism by which KRAS G12D leads to defects in mitosis, we treated H2B-GFPexpressing HeLaG12D cells with doxycycline for 24 h, then added two different MEK1/2 inhibitors: the first-generation compound, U0126, and the highly potent and selective inhibitor, AZD6244. Treatment with either inhibitor prevented mitotic delay as well as the appearance of mitotic defects triggered by KRAS G12D expression (Fig. 1e,f) . This result suggests that mitotic abnormalities elicited by oncogenic KRAS expression require MAPK pathway activation.
To further analyse the mitotic defects in HeLaG12D cells, we looked at the ability of KRAS G12D -expressing cells to form a stable bipolar spindle upon release from a Monastrol block 19, 20 . Interestingly, the majority of doxycycline-treated HeLaG12D cells exhibited metaphase spindles with abnormal geometry upon Monastrol washout, with poles often out of line with normal spindle orientation ( Supplementary Fig. S4a-c) . Spindles also appeared longer and narrower than in control, non-induced cells ( Supplementary Fig. S4d ,e). These results suggest expression of KRAS G12D influences one or more processes essential for mitotic progression. In fact, quantitative PCR analysis showed expression of several mitosis-related genes was down-regulated in doxycycline-treated HeLaG12D cells prior to mitotic entry ( Supplementary Fig. S5 ), providing a potential explanation for the observed mitotic defects in these cells. The list of de-regulated mitotic genes includes centromere protein A (CENPA) and centromere protein M (CENPM), which encode proteins essential for the assembly of a functional kinetochore 21 , cohesin associated factor PDS5B
22
, and several genes encoding proteins involved in mitotic spindle formation and/or maintenance, such as microtubule-associated protein 7 (MAP7, also known as Ensconsin or E-MAP-115) 23, 24 , large tumour suppressor kinase 2 (LATS2) 25 and kinesin family member 2C (KIF2C, also known as MCAK) 26, 27 . We then decided to check whether expression of KRAS G12D provokes mitotic defects in a different cell line. For this purpose, we stably integrated GFP-tagged histone H2B into an isogenic pair of lung cancer cell lines that only differ in their KRAS genotype (NCI-H1975 KRAS +/+ and KRAS
G12D/+
), and monitored cell division by time-lapse microscopy. As shown in Fig. 2a , GFP-H2B-expressing KRAS G12D/+ cells displayed a higher incidence of chromosome alignment and segregation defects compared to the parental NCI-H1975 KRAS +/+ cells, suggesting KRAS G12D -triggered mitotic defects are not a phenotype exclusive of HeLa cells. We then engineered immortalised, non-transformed retinal pigment epithelial cells (hTERT-RPE-1; hereafter referred as RPE) to express KRAS G12D upon doxycycline treatment. Interestingly, doxycycline-treated RPEG12D cells did not display errors in mitosis or a delay in mitotic progression when compared to un-induced RPEG12D cells ( Supplementary Fig. S6a,b) . We noticed however that expression of ectopic KRAS G12D protein was lower in the polyclonal RPEG12D population than in HeLaG12D cells (data not shown), prompting us to investigate whether the increased expression levels of KRAS G12D were responsible for the induction of mitotic defects. To address this possibility, we first monitored mitotic progression in 3 independent HeLaG12D clones. As shown in Fig. 2b ,c, mitotic defects and delay were only observed in clones 3 and 4, which show higher expression of KRAS G12D than clone 11 ( Supplementary Fig. S6c ). This result suggests that elevated levels of KRAS G12D expression may be required for the induction of errors in progression through mitosis. We then analysed mitotic progression in RPEG12D clone 4, which expresses KRAS G12D at levels comparable to the HeLaG12D polyclonal population ( Supplementary Fig. S6c) . Surprisingly, no mitotic defects were observed in these cells either ( Supplementary Fig. S6d,e) , suggesting elevated expression of oncogenic KRAS per se is insufficient to trigger defective cell division.
Interestingly, we noticed that RPEG12D cells were unable to fully activate the MAPK pathway, as measured by their inability to induce translocation or ERK1/2 into the nucleus upon doxycycline treatment ( Supplementary Fig. S6f and data not shown) . However, translocation of ERK1/2 into the nucleus was readily apparent in HeLaG12D cells, both in the polyclonal population and in individual clones 3 and 4 ( Fig. 2d and Supplementary Fig. S1 ). These results suggest that the inability of KRAS G12D to fully activate MAPK pathway in RPE cells might be responsible for the lack of induction of mitotic defects in these cells, consistent with the fact that KRAS G12D -triggered mitotic errors in HeLa cells are mediated by MEK (see Fig. 1 ). To test this hypothesis, we treated RPEG12D cells with EGF, which induces hyper-activation of the MAPK pathway independently of oncogenic KRAS activation. Strikingly, EGF-treated RPEG12D cells showed an increase in the incidence of mitotic errors (Fig. 2e) . Taken together, our results suggest that abnormal activation of the MAPK pathway, which occurs in most cell types following oncogenic KRAS activation, results in defective mitotic progression.
Oncogenic KRAS expression increases sensitivity to anti-mitotic drugs. We hypothesized that the mitotic delay observed in HeLaG12D cells could enhance sensitivity to treatments perturbing normal mitotic progression. Indeed, the colony-forming ability of doxycycline-treated HeLaG12D cells was reduced compared to untreated cells when cultured in the presence of the kinesin Eg5 inhibitors Monastrol or S-trityl-L-cysteine (STLC; Fig. 3a) . As a control, we treated HeLa parental cells with doxycycline, then with Eg5 inhibitors. As shown in Supplementary Fig. S7a , no differences in colony-forming ability were observed in doxycycline-treated vs. untreated parental cells challenged with Eg5 inhibitors. Importantly, expression of KRAS G12D on its own sufficed to reduce colony formation (Fig. 3a , white bars, DMSO), indicating KRAS G12D expression has anti-proliferative effects in HeLa cells and consistent with the fact that it compromises mitotic cell division. Indeed, when doxycycline-treated HeLaG12D cells were followed by time-lapse microscopy over a period of 2 days after release from a double thymidine block, it was apparent that abnormal divisions induced by KRAS G12D expression led to a higher incidence of death of 'grand-daughter' cells (Supplementary Table S1 ). This finding is consistent with the decreased ability of these cells to form colonies in the long term.
Interestingly, we also observed signs of apoptosis (as determined by cleavage of caspase-3 and PARP) as early as 24 h after Eg5 inhibition in doxycycline-treated vs. untreated HeLaG12D cells ( Fig. 3b and Supplementary Fig. S7b ), indicating the combination of anti-mitotic drug treatment with acute KRAS G12D expression leads to premature cell death. Similar results were observed when challenging cells with paclitaxel ( Supplementary Fig. S7c ). To investigate this phenotype in more detail, we performed phase-contrast time-lapse imaging of doxycycline-treated HeLaG12D cells upon addition of 50 μ M Monastrol, half the concentration required for maximal Eg5 inhibition 20 . As shown in Fig. 3c , control HeLaG12D cells (-doxycycline) were only partially delayed in mitosis (median value = 180 minutes) and the majority of cells stayed alive during the period of filming (48 hours). In contrast, Monastrol treatment led to a significant delay in mitosis in doxycycline-treated HeLaG12D cells, with 50% of cells dying during this protracted mitotic arrest (Fig. 3c,d ). At higher concentrations of Monastrol (100 μ M), the difference between doxycycline-treated and untreated HeLaG12D cells was still apparent albeit less significant (80% cells dying during mitosis + doxycycline, compared to 50% -doxycycline; Fig. 3e ). Similar results were observed with a different Eg5 inhibitor (STLC) and with a different spindle poison (paclitaxel; Fig. 3f and Supplementary  Fig. S7d ). Of note, low concentrations of paclitaxel (5-10 nM), comparable to the intracellular level of paclitaxel in treated patients and cell lines 28 , were required to expose different sensitivity between doxycycline-treated and untreated HeLaG12D cells ( Fig. 3f and Supplementary Fig. S7c ,e). At these concentrations, the mitotic delay was mild (median value = 107 minutes -doxycycline, 130 minutes + doxycycline; n = 30 cells analysed per condition; Supplementary Fig. S7e , left panel). At higher concentrations (30-100 nM), the delay in mitosis was more pronounced and, although all cells died in mitosis irrespective of doxycycline exposure, KRAS G12D -expressing HeLa cells (+ Dox) died significantly faster than non-expressing cells (-Dox; Supplementary Fig. S7e , middle and right panels), suggesting KRAS G12D expression primes cells for the induction of apoptosis, leading to faster cell death upon anti-mitotic drug treatment. Taken together, these results suggest expression of KRAS G12D can lead to increased sensitivity to anti-mitotic agents by two mechanisms: by lowering the death threshold prior to mitotic entry, and by delaying mitotic progression, which allows for death signals to accumulate.
Transcriptional down-regulation of BCL-XL by MYC mediates cell death in response to anti-mitotic treatments in KRAS
G12D -expressing cells. To explore the mechanism of cell death of KRAS G12D -expressing cells after exposure to anti-mitotic chemotherapeutics, we focused on the well-established connection between oncogenic RAS and MYC. Expression of oncogenic RAS leads to up-regulation of the transcription factor MYC via ERK-mediated phosphorylation and subsequent protein stabilisation 29, 30 . As described above (see Fig. 1b ), HeLaG12D cells display increased expression levels of MYC, confirming this observation. MYC is known to regulate transcription of several members of the BCL-2 protein family, key mediators of apoptotic cell death, in several contexts [31] [32] [33] [34] . Furthermore, MYC has been recently shown to be a key mediator of cell death in response to anti-mitotic drugs 18 . Therefore, we hypothesized that up-regulation of MYC in KRAS G12D -expressing cells might result in elevated expression of pro-apoptotic proteins and/or reduced expression of anti-apoptotic proteins, leading to accelerated cell death after challenge with anti-mitotic drugs. To test this hypothesis, we transfected doxycycline-treated HeLaG12D cells with siRNA oligos targeting MYC. Twenty-four hours after transfection, cells were treated with paclitaxel and immediately monitored The prevailing model of cell fate regulation in response to anti-mitotic drugs hints at the existence of a yet unidentified death signal which accumulates during drug-induced mitotic arrest 18, 35 . In order to test the possibility that MYC might mediate such a death signal, and to elucidate the mechanism by which it might do so, we 
, MYC levels dropped rapidly upon entry into mitosis in both doxycycline-treated and untreated cells: by 12 h post-release (when ∼ 80% cells had already entered mitosis), MYC levels were almost undetectable ( Supplementary Fig. S8b,c) . This result indicates that MYC protein levels do not increase during mitotic arrest. On the contrary, they decrease rapidly. These findings therefore suggest that MYC abundance during mitosis does not determine cell fate upon exposure to anti-mitotic drugs.
Several members of the BCL-2 protein family have been involved in determining the response to anti-mitotic agents, including anti-apoptotic proteins BCL-XL and MCL-1 (reviewed in 35 ). Since transcription of several of these genes is controlled by MYC [31] [32] [33] [34] , we reasoned that MYC-mediated regulation of death in response to anti-mitotics might be dependent on regulation of expression of one or more of these apoptotic proteins. Interestingly, we found that BCL-XL expression was lower in doxycycline-treated HeLaG12D cells transfected with control siRNA oligos (Fig. 4b) , thus providing a potential explanation for the increased lethality of KRAS G12D -expressing HeLa cells, both in the absence and in the presence of anti-mitotic drugs (see Fig. 3 and Supplementary Fig. S7 ). Moreover, we found that expression of BCL-XL and MCL-1 was up-regulated following MYC knockdown (Fig. 4b) . Conversely, expression of pro-apoptotic protein BIM, which has also been involved in determining paclitaxel sensitivity, was severely down-regulated following MYC knockdown, especially following doxycycline treatment (Fig. 4b) . These results suggest KRAS G12D controls expression of anti-apoptotic protein BCL-XL, thus generating a pro-death environment that can be exploited by anti-mitotic drug treatment. Furthermore, our results, in agreement with what has been recently reported 18 , indicate MYC controls the expression of a network of proteins with known roles in determining apoptotic response to anti-mitotic agents. Importantly, by co-transfecting HeLaG12D cells with siRNA oligos targeting BCL-XL and MYC, we found that the rescue of cell death observed following MYC knockdown was abolished by simultaneous BCL-XL depletion (Fig. 4c,d ). Not only was death in mitosis enhanced, but so was the death of daughter cells upon mitotic exit (Fig. 4e) . These results indicate that MYC-mediated down-regulation of anti-apoptotic protein BCL-XL mediates sensitisation to anti-mitotic drugs induced by KRAS
G12D
. Whether down-regulation of MCL-1 and/or up-regulation of BIM play a role in this context is still unclear.
KRAS-mutant cancer cells are not selectively sensitive to anti-mitotic drugs. The MYC-dependent increased sensitivity to anti-mitotic chemotherapeutics in KRAS G12D
-expressing HeLa cells prompted us to evaluate the possibility of using these widely drugs to selectively kill KRAS-mutant tumours, a strategy previously suggested by others 2 . For this purpose, we analysed a panel of KRAS-mutant cancer cell lines for their response to a 48-hour treatment with STLC. Apoptotic cell death was measured by Annexin-V staining, and 5 cell lines encoding wild-type KRAS were used as controls. As shown in Fig. 5a , we observed no correlation between response to STLC treatment and KRAS mutational status.
We reasoned that genetic alterations in these cancer cell lines other than mutations in KRAS might affect their response to anti-mitotics. To rule this out, and to monitor the role exclusively of KRAS G12D , we again used the isogenic pair NCI-H1975 KRAS +/+ and KRAS G12D/+ . Strikingly, NCI-H1975 KRAS G12D/+ cells were slightly less sensitive to both paclitaxel and STLC when compared to their wild-type isogenic counterparts ( Fig. 5b and Supplementary Fig. S9a,b) . We note that this small difference might be due to differences in proliferation rate. Indeed, NCI-H1975 KRAS G12D/+ cells grow slightly slower than NCI-H1975 KRAS +/+ cells ( Supplementary Fig. S9c ). Similarly, no apparent increase in sensitivity to STLC was observed when using a different isogenic pair of cancer cell lines: SW48 KRAS +/+ and KRAS G12D/+ (Supplementary Fig. S9d ). Interestingly, no differences in the response to STLC, measured by a short-term apoptosis assay ( Supplementary Fig. S9e ) or by a long-term colony forming assay ( Supplementary Fig. S9f ), were observed when comparing isogenic colorectal cancer cell lines HCT116 KRAS +/− and KRAS
+/G13D
, which were previously used to uncover sensitivity to several mitotic perturbations such as inhibition of PLK1 2 . Note that, although we cannot rule out the possibility that differences in methodology may explain the apparent discrepancy between our study and that of Luo and colleagues 2 , our results indicate that mutations in KRAS do not universally confer sensitivity to anti-mitotic drug treatments. An alternative explanation could be that cells' response to anti-mitotic agents might be differentially regulated by different mutations in KRAS (G12D in NCI-H1975 and SW48 isogenic pairs, as opposed to G13D in HCT116), consistent with the notion that different KRAS mutants generate distinct signalling network signatures 36 . We extended our analysis to a larger panel of cancer cell lines, by surveying the Genomics of Drug Sensitivity in Cancer database 37 , which contains information for 665 cell lines and 141 drugs, 10 of which are anti-mitotics. We sub-classified the cell lines into those wild-type or mutant for KRAS, using the associated genomic data, then obtained half-maximal inhibitory concentration (IC50) for each anti-mitotic drug (obtained using 72-hour viability assays) and plotted the mean IC50 values for each drug against KRAS mutational status. Strikingly, we observed no correlation between sensitivity to anti-mitotic drugs and KRAS status (Fig. 5c , Supplementary Table S2 and Supplementary Fig. S10a ). Similar results were obtained when analysing drug response data for the NCI-60 cell line panel ( Supplementary Fig. S10b 38 ).
KRAS-mutant cells expressing high levels of MYC are sensitive to anti-mitotic drugs. It has been
recently suggested that elevated MYC levels might predict anti-mitotic drug sensitivity 18 , a hypothesis supported by our own observations (see Fig. 4 ). To test this hypothesis, we again utilised the Genomics of Drug Sensitivity database, where MYC gene expression data are available for 625 out of a total of 665 cell lines tested. Cell lines were arranged according to their MYC expression levels, and IC50 values for the 10 anti-mitotic drugs used in this database were plotted for the top 50 and the bottom 50 MYC-expressing cell lines. Unexpectedly, no significant differences in IC50 values were observed when comparing cell lines with elevated levels of MYC against those with low MYC expression (Fig. 6a) , questioning the proposal that MYC expression alone is a reliable biomarker for anti-mitotic drug responses, and suggesting that other factors must also be involved.
We then sub-classified these 625 cell lines into wild-type or mutant for KRAS, and plotted IC50 values for the microtubule-interfering agents vinblastine, vinorelbine, docetaxel and epothilone-B, and the Aurora B inhibitor ZM447439, in relation to MYC gene expression as above. We note that IC50 values for the other 5 anti-mitotic drugs used in this database (STLC, VX-680, BI-2536, GW843682X and paclitaxel) were restricted to only ~20 KRAS-mutant cell lines in each case, so we did not include these drugs in the analysis. MYC gene expression data were only available for 77 out of 85 KRAS-mutant cell lines in this database, so we only plotted IC50 values for the top 10 MYC-expressing KRAS-mutant cell lines compared to the bottom 10 expressing lines. Strikingly, a lower IC50 (corresponding to increased sensitivity) was observed for the top MYC-expressing KRAS-mutant cell lines compared to the bottom MYC-expressing lines (Fig. 6b) . We note that statistical significance is only achieved with epothilone-B (p < 0.01, Mann Whitney test), but the other 3 drugs show a similar trend. Interestingly, there was no difference in the IC50 for ZM447439 (data not shown), which unlike the microtubule-targeting drugs does not prolong mitotic arrest but instead accelerates mitotic exit 39 . We then performed the same analysis on the ∼ 520 KRAS-wild-type cell lines for which MYC gene expression and IC50 data were available. Strikingly, no obvious differences were observed in the IC50 values for vinorelbine, vinblastine, docetaxel or epothilone-B when comparing the top MYC-expressing KRAS-wild-type cell lines with the bottom MYC-expressing lines (Fig. 6b) . Taken together, these results suggest that KRAS-mutant cancer cell lines expressing high levels of MYC are especially sensitive to microtubule-interfering agents, opening up new avenues for therapeutic intervention. Furthermore, they suggest MYC expression might not serve as a sole predictor of sensitivity to anti-mitotic drugs, but instead point to a potential cooperative effect of KRAS mutation and high MYC expression in determining anti-mitotic drug response.
Discussion
In this study, by combining the use of isogenic cell line pairs with a targeted bioinformatics analysis of a publicly available database and the study of mitosis progression in cultured epithelial cancer cells upon acute expression of oncogenic KRAS, we make several observations with important implications for cancer biology and therapy. Unexpectedly, we find no correlation between anti-mitotic drug response and KRAS status in archival analysis of over 600 cancer cell lines, in experimental comparison of a panel of 5 KRAS-wild-type and 10 KRAS-mutant cancer cell lines, or when measuring induction of apoptotic cell death in three independent isogenic paired cell lines treated with anti-mitotic drugs (see Fig. 5 and Supplementary Figs S9 and S10) . Thus, our results -arising from three independent methods -question the proposal that anti-mitotic drugs may preferentially kill KRAS-mutant cancer cells, and caution against the use of KRAS mutational status alone as a predictive marker for patient stratification.
However, we find that acute over-expression of KRAS G12D in HeLa cells leads to aberrant progression through mitosis. This phenotype is dependent on MAPK pathway activation, as it is rescued, at least partly, by MEK inhibition (see Fig. 1 ). Similar results have been reported when HRAS G12V was over-expressed in mouse NIH/3T3 cells 13 , rat thyroid cells 14 or primary human fibroblasts 17 . However, to our knowledge, this is the first time such phenotype is described upon expression of KRAS G12D , the most prevalent RAS mutation in cancer, in human cells. Anaphase bridges are observed in ∼ 15% of human pancreatic ductal adenocarcinomas (PDAs) 10 and in PDAs and liver metastases of Kras and Trp53 double mutant mice 40 . Our results suggest KRAS G12D expression may play a role in the appearance of these mitotic abnormalities, possibly by de-regulating expression of one or more mitosis-related genes prior to mitotic entry (see Supplementary Fig. S5 ).
Interestingly, acute expression of KRAS G12D in non-transformed RPE cells does not elicit the same mitotic phenotypes as in HeLa cells, probably due to a lack of full MAPK pathway activation in the former (see Supplementary Fig. S6 ). This result indicates that mitotic defects are not a universal phenotype downstream of KRAS G12D activation; instead, they are likely to be dependent on cell type and, more specifically, on the ability of KRAS G12D to activate the MAPK pathway above a certain threshold required to elicit gene expression changes which result in de-regulation of the mitotic machinery.
Notably, we find that acute expression of KRAS G12D in HeLa cells also leads to increased sensitivity to anti-mitotic drugs. Our findings indicate that this phenotype is mediated by the ability of oncogenic KRAS to up-regulate MYC, which itself regulates transcription of several apoptotic genes in other contexts [31] [32] [33] [34] . This is in agreement with a recent report showing that MYC is a key mediator of anti-mitotic drug responses 18 . In particular, we show here that RNAi-mediated depletion of MYC leads to up-regulation of anti-apoptotic proteins BCL-XL and MCL-1, as well as down-regulation of pro-apoptotic protein BIM. Moreover, BCL-XL knockdown abolishes the rescue of cell death observed following MYC down-regulation, suggesting a model wherein BCL-XL works downstream of MYC as a major determinant of cell death in response to anti-mitotic agents. Interestingly, previous reports suggest a role for BCL-XL in mediating anti-mitotic drug responses 41 . Our work, together with that of Topham and colleagues 18 , confirms this finding, and establishes MYC as a key regulator of cell fate in response to anti-mitotics by working upstream of BCL-XL.
Quantitative PCR analysis of MCL-1 following MYC RNAi showed no changes at the mRNA level (data not shown), suggesting MYC regulates MCL-1 at a post-transcriptional level. Interestingly, proteasomal degradation of MCL-1, mediated by ubiquitin ligases APC/C and FBW7, has been shown to play a key role in cell fate during drug-induced mitotic arrest 42, 43 . Whether MYC-mediated modulation of MCL-1 levels also plays a role in determining anti-mitotic drug response is yet unclear. We also find that levels of pro-apoptotic protein BIM are regulated by MYC in KRAS G12D -expressing HeLa cells (see Fig. 4b ). Whether MYC-mediated regulation of BIM occurs at the transcriptional or post-transcriptional level, and whether this regulation plays a role in determining anti-mitotic drug response, is still unclear.
We find -as expected from the short half-life of both MYC mRNA and protein 44, 45 , coupled to the near-complete cessation of de novo protein synthesis during mitosis 46, 47 -that MYC protein levels quickly drop during drug-induced mitotic arrest (see Supplementary Fig. S8b,c) . This suggests that MYC regulates the transcription of apoptotic genes in interphase so that, upon mitotic entry, cells are primed for death if mitosis should be delayed. In other words, MYC may determine the 'death threshold' before cells enter mitosis. We propose that this mechanism acts in concert with other layers of regulation of death in response to anti-mitotics that directly rely on accumulation of death signals during prolonged mitotic arrest, such as SCF FBW7 -dependent proteasomal degradation of MCL-1 42, 43 , phosphorylation of BCL-2, BCL-XL and BID 48, 49 , cyclin G1 over-expression 50 , caspase-9 dephosphorylation 51 or telomere deprotection 52 . However, it is yet unclear whether these mitotic death signals co-exist in every cell, and so it is conceivable that drug responses might be regulated by different pathways in different tissues or cell types, consistent with the reported variability in anti-mitotic drug responses across multiple cell lines 53, 54 . Finally, we demonstrate here for the first time that KRAS-mutant cancer cell lines expressing elevated levels of MYC show increased sensitivity to several microtubule-interfering agents, opening up new avenues for therapeutic intervention and suggesting new strategies for patient stratification. Our study therefore bridges two key areas of cancer therapy: the use of anti-mitotic chemotherapeutics for the treatment of several types of cancer (where a clear understanding of the factors determining patients' response is still lacking) and the long-standing, yet largely unsuccessful efforts to treat tumours harbouring mutant KRAS, which account for 20-25% of all human cancers.
Methods
Cell culture and reagents. Isogenic 55, 56 . Stable integrants were selected with 4 μ g/ml blasticidin (Invivogen) and 200 μ g/ml hygromycin (Roche) for HeLa, or 10 μ g/ml blasticidin and 400 μ g/ml G418 (Life Technologies) for RPE. Transgene expression was achieved by treatment with 0.1 μ g/ml doxycycline (Sigma). Other chemicals were obtained from the following suppliers: Tocris Bioscience (monastrol and STLC), Sigma (thymidine and paclitaxel), Cell Signalling (EGF), Calbiochem (U0126) and Selleckchem (AZD6244). Knockdown experiments were performed by transfecting cells with siRNA oligos at 25 nM (Supplementary Table S3 ), using jetPRIME transfection reagent (Polyplus).
Immunoblotting. Cells were lysed in RIPA buffer and proteins quantified using BCA assay (Thermo Scientific). Proteins were loaded onto NuPAGE pre-cast gels (Life Technologies) and transferred onto HyBond ECL nitrocellulose membranes (GE Healthcare). Membranes were blocked in TBST (10 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.1% Tween-20) plus 5% non-fat dry milk for 1 hour, before incubation with the antibodies listed in Supplementary Table S4 , overnight at 4 °C. Following washes with TBST, membranes were incubated with HRP-conjugated secondary antibodies (GE Healthcare) and developed using SuperSignal West Pico chemiluminescent substrate (Thermo Scientific).
Live cell imaging. Cells were grown on multi-well 1.0-mm-thick borosilicate chamber slides (Lab-Tek).
Phase-contrast time-lapse microscopy was performed on a Zeiss Axiovert 200M microscope, acquiring images every 5 minutes under a 20X objective. To visualise chromatin, GFP-tagged histone H2B was subcloned from pH2B-GFP (Addgene 11680) into pcDNA3.1/puro (kind gift from Chris Sullivan, University of Texas). The H2B-GFP transgene was then stably integrated into the required cell lines, which were selected with puromycin (Invivogen). Fluorescence live-cell imaging was performed on a Leica DMI6000 microscope using a HCX PL APO objective (40X magnification, N.A. 0.85), and images acquired every 5 minutes on an Evolve 512 EMCCD camera (Photometrics) using LAS AF software, then processed and analysed with ImageJ (NIH, Bethesda, Maryland).
Colony forming assays. Cells were treated with doxycycline for 48 hours before plating in triplicate on 6-well dishes, at a dilution of 200 cells per well. Anti-mitotic drugs were then added for 72 hours, then washed out and cells allowed to grow for a further 5 days in the presence or absence of doxycycline. Cells were then fixed in 4% formaldehyde, washed in PBS and stained with 0.1% crystal violet (Sigma) for 20 minutes before washing with water. Plates were allowed to dry overnight and colonies were counted using ColCount (Oxford Optronix).
Flow cytometry. For measurement of apoptosis, cells were plated on 6-well dishes at a dilution of 200,000 cells per well. Anti-mitotic drugs were added the following day and cells harvested 48 hours later. Apoptotic cells were detected by Annexin-V staining using Annexin-V/FITC Apoptosis Detection Kit II (BD Biosciences), according to manufacturer's instructions, and analysed on a Becton Dickinson LSR II flow cytometer. Data was processed with FlowJo software. For cell cycle analysis, cells were fixed in ethanol, blocked in PBS with 0.1% Triton X-100 (PBST) and 1% BSA for 30 minutes, then incubated with mouse anti-phospho-MPM2 antibody 1:500 (Millipore) for 2 h at room temperature. Following washes with blocking solution, cells were incubated with Alexa Fluor 488 secondary antibody (Life Technologies) for 1 h, washed with PBST and treated with 40 μ g/ml propidium iodide (Sigma) and 200 μ g/ml RNaseA (Sigma), then analysed as above.
Immunofluorescence and image analysis. For mitotic spindle analysis, cells grown on coverslips were treated with 100 μ M Monastrol for 4 h, then washed 3 times with normal growth media and released into media containing 20 μ M MG132 (Calbiochem) for 2 h to block metaphase-to-anaphase transition. Cells were then permeabilised for 90 s in K-buffer (100 mM PIPES pH 6.8, 1 mM MgCl 2 , 0.1 mM CaCl 2 , 0.1% Triton X-100) to preserve K-fibres, and fixed for 10 min in 4% formaldehyde diluted in K-buffer. Following washes in PBS with 0.1% Triton X-100 (PBST), cells were blocked in PBST plus 5% milk, incubated with mouse monoclonal anti-β -Tubulin 1:1000 (clone D66, Sigma) for 30 min, then incubated with Alexa Fluor 568 secondary antibody 1:500 (Life Technologies) for another 30 min. Following washes in PBST, coverslips were mounted and counterstained with DAPI-containing VectaShield (Vector Labs). Images were acquired as 1 μ m-step Z-stacks on a Leica SP5 laser scanning confocal microscope using a 100x objective (N.A. 1.4), and analysed and processed using ImageJ.
For co-staining of ERK1/2 and myc-tagged KRAS, cells grown on coverslips were fixed in 4% formaldehyde diluted in PBS for 10 min at room temperature. Following washes in PBST, cells were blocked in PBST plus 1% BSA for 30 min, then incubated with mouse monoclonal anti-Myc tag 1:500 (clone 4A6, Millipore) and rabbit monoclonal anti-ERK1/2 1:100 (clone 137F5, Cell Signalling) for 1 h at room temperature. Following washes in PBST, cells were incubated with Alexa Fluor 488 or 568 secondary antibodies diluted 1:500, then mounted as above. Images were acquired as 1 μ m-step Z-stack tile scans on a Leica SP5 laser scanning confocal microscope using a 63x objective (N.A. 1.4) . Nucleo-cytoplasmic ratio of ERK1/2 was measured using ImageJ. Briefly, a nuclear mask was created using the DAPI image, then superimposed on the ERK1/2 image to quantify nuclear signal. The cytoplasmic signal intensity was then quantified from the inverse image once the extracellular background signal was removed.
Extraction of RNA and quantitative PCR. Total RNA was obtained using the RNeasy mini kit (Qiagen), according to manufacturer's instructions, and cDNA was generated from 1 μ g RNA using the Cloned AMV First-Strand cDNA Synthesis Kit (Invitrogen), using Oligo(dT)20 primers and Random Hexamers. Quantitative PCR was performed on the LightCycler 480 (Roche) using LightCycler 480 SYBR Green I Master Mix (Roche), according to the manufacturer's recommendations. Gene-specific primers were designed manually or using Primer-BLAST (NCBI), purchased from Sigma, tested in a standard PCR reaction for generation of a single band only, and used at a final concentration of 0.25 μ M (see Supplementary Table S5 
Statistical analyses.
All statistical analyses were performed using GraphPad Prism version 5 (GraphPad Software).
